Nuveen
MIRM icon

Nuveen’s Mirum Pharmaceuticals MIRM Stock Holding History

Nuveen’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.5M Sell
329,282
-144,945
-31% -$14.6M 0.01% 860
2026
Q1 		$43.8M Sell
474,227
-28,818
-6% -$2.71M 0.01% 713
2025
Q4 		$39.7M Sell
503,045
-98,625
-16% -$7.08M 0.01% 762
2025
Q3 		$44.1M Buy
601,670
+11,413
+2% +$726K 0.01% 688
2025
Q2 		$30M Sell
590,257
-64,465
-10% -$2.87M 0.01% 860
2025
Q1 		$29.5M Sell
654,722
-67,433
-9% -$3.18M 0.01% 885
2024
Q4 		$29.9M Buy
722,155
+229,746
+47% +$9.57M 0.01% 918
2024
Q3 		$19.2M Buy
492,409
+85,290
+21% +$3.4M 0.01% 1220
2024
Q2 		$13.9M Buy
407,119
+95,934
+31% +$2.52M ﹤0.01% 1368
2024
Q1 		$7.82M Sell
311,185
-159,155
-34% -$4.38M ﹤0.01% 1746
2023
Q4 		$13.9M Buy
470,340
+37,557
+9% +$1.14M ﹤0.01% 1381
2023
Q3 		$13.7M Buy
432,783
+357,183
+472% +$9.78M ﹤0.01% 1287
2023
Q2 		$1.96M Buy
75,600
+3,906
+5% +$104K ﹤0.01% 2366
2023
Q1 		$1.72M Sell
71,694
-1,554
-2% -$35.4K ﹤0.01% 2397
2022
Q4 		$1.43M Sell
73,248
-10,497
-13% -$207K ﹤0.01% 2523
2022
Q3 		$1.76M Buy
83,745
+44,942
+116% +$1.08M ﹤0.01% 2459
2022
Q2 		$756K Sell
38,803
-36,752
-49% -$867K ﹤0.01% 2903
2022
Q1 		$1.67M Buy
75,555
+64,535
+586% +$1.32M ﹤0.01% 2586
2021
Q4 		$150K Hold
11,020
– – ﹤0.01% 3262
2021
Q3 		$199K Hold
11,020
– – ﹤0.01% 3278
2021
Q2 		$191K Sell
11,020
-3,300
-23% -$59.1K ﹤0.01% 3250
2021
Q1 		$284K Sell
14,320
-10,491
-42% -$201K ﹤0.01% 3183
2020
Q4 		$433K Sell
24,811
-135
-0.5% -$2.65K ﹤0.01% 3073
2020
Q3 		$481K Buy
24,946
+14,550
+140% +$312K ﹤0.01% 2966
2020
Q2 		$202K Buy
+10,396
New +$174K ﹤0.01% 3101

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's MIRM Position: Q2 2026 in Review

Nuveen reduced its Mirum Pharmaceuticals (MIRM) stake by 31% in Q2 2026, selling an estimated $14.6M and leaving 329,282 shares worth $38.5M. The position accounts for 0.01% of the portfolio, ranked #860.

Nuveen first reported a position in MIRM in Q2 2020 and has held it in 25 quarters since. The position peaked at $44.1M in Q3 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Nuveen held 329,282 shares of Mirum Pharmaceuticals worth $38.5M as of Q2 2026.
  • Nuveen sold 144,945 Mirum Pharmaceuticals shares in Q2 2026, an estimated $14.6M.
  • Mirum Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q2 2026, its #860 holding.
  • Nuveen first reported a position in Mirum Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Nuveen's Mirum Pharmaceuticals position peaked at $44.1M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.